ALP Life Sciences, Inc. (ALP) was founded by brothers, physician Robert A. Barker, MD, and David K. Barker. Dr. Robert Barker, Chairman of ALP Life Sciences, is a founding physician of Parkway Medical Group in Asheville, North Carolina. Dr. Barker has been a family physician for over 30 years and like physicians around the world, encounters the increasing challenge of chronic inflammatory diseases in his patients every day. Prior to ALP, David was founder and CEO, 1997-2007, of a life sciences research and services company serving the sales and marketing needs of the global life sciences industry. That private company was sold to a publicly traded healthcare company and continues to serve the industry with innovative solutions.
ALP Life Sciences, Inc. (ALP) is a nutritional medicine company created for the purpose of managing a natural botanical drug development project for treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). ALP is the sponsor of an ongoing research project (NV-1002) for treatment of fatty liver diseases. Fatty liver related diseases are an emerging global epidemic in both the developed and emerging world. The ALP mission is to conduct lipid metabolism research and offer or license new products for unmet medical needs. During ongoing NV-1002 NASH research ALP recognized the need for an optimally formulated omega 3 fish oil product to maximize omega 3 metabolism and uptake in patients. The ALP High 3 fish oil supplement is the solution to this need. The emerging science of Applied Lipid Polymorphism “ALP” is simply the use of appropriate doses and formulations of lipids as nutritional medicine. ALP is focused on commercializing botanical drug Rx products or OTC products to facilitate the remodeling of lipids in the human body to treat chronic inflammatory diseases and optimize human health.